Clinical Trials Browser

Interventional × HER2-low Breast Cancer × 90 days × Clear all

NCT07446452 2026-03-03

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Phase 2 Recruiting

HER2-low Breast Cancer

NCT06957886 2026-01-21

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Phase 3 Recruiting

HER2-low Breast Cancer